01:27 PM EST, 11/11/2024 (MT Newswires) -- Citius Pharmaceuticals ( CTXR ) shares jumped 11% in recent trading Monday after the company said that Lymphir was found to benefit cancer patients in an early-stage study when combined with pembrolizumab.

Preliminary results from an investigator-initiated phase 1 clinical trial found that over a quarter of evaluable patients responded to the treatment, the company said.

The study enrolled 21 patients with recurrent or metastatic solid tumors, of which 15 were eligible for evaluation.

One third of the evaluable patients experienced some form of clinical benefit, the company said, adding that of those that benefited, the median time without disease progression was 57 weeks.

Meanwhile, two of the four patients who had a partial response had previously been treated with anti-PD-1 therapies, suggesting that the addition of Lymphir may boost the effectiveness of anti-PD-1 drugs in patients who no longer respond to similar treatments, the company said.

Price: 0.46, Change: +0.05, Percent Change: +11.18